米国企業
Tarsus Pharmaceuticals, Inc.

Tarsus Pharmaceuticals, Inc.TARS

時価総額

$11.4億

PER

	2023年 12月31日
Net loss	-136
Depreciation	1
Stock-based compensation	20
Amortization of intangible assets	0
Accretion of term loan-related costs	0
Stock-based compensation	20
Non-cash lease expense	1
Accretion of term loan-related costs	0
Non-cash lease expense	1
Net amortization/accretion on marketable securities	3
Unrealized (gain) loss on equity investment	0
Change in fair value of equity warrants issued by licensee	0
Other receivables	-2
Accounts receivable, net	17
Prepaid expenses	3
Inventory	3
Other non-current assets	1
Other receivables	-2
Accounts payable and other accrued liabilities	13
Prepaid expenses	3
Accrued payroll and benefits	8
Other non-current assets	1
Other long-term liabilities	0
Accounts payable and other accrued liabilities	13
Accrued payroll and benefits	8
Other long-term liabilities	0
Other receivables	-2
Accounts receivable, net	17
Prepaid expenses	3
Inventory	3
Other non-current assets	1
Other receivables	-2
Accounts payable and other accrued liabilities	13
Prepaid expenses	3
Accrued payroll and benefits	8
Other non-current assets	1
Other long-term liabilities	0
Accounts payable and other accrued liabilities	13
Accrued payroll and benefits	8
Other long-term liabilities	0
Net cash used in by operating activities	-117
Net loss	-136
Depreciation	1
Stock-based compensation	20
Amortization of intangible assets	0
Accretion of term loan-related costs	0
Stock-based compensation	20
Non-cash lease expense	1
Accretion of term loan-related costs	0
Non-cash lease expense	1
Net amortization/accretion on marketable securities	3
Unrealized (gain) loss on equity investment	0
Change in fair value of equity warrants issued by licensee	0
Other receivables	-2
Accounts receivable, net	17
Prepaid expenses	3
Inventory	3
Other non-current assets	1
Other receivables	-2
Accounts payable and other accrued liabilities	13
Prepaid expenses	3
Accrued payroll and benefits	8
Other non-current assets	1
Other long-term liabilities	0
Accounts payable and other accrued liabilities	13
Accrued payroll and benefits	8
Other long-term liabilities	0
Other receivables	-2
Accounts receivable, net	17
Prepaid expenses	3
Inventory	3
Other non-current assets	1
Other receivables	-2
Accounts payable and other accrued liabilities	13
Prepaid expenses	3
Accrued payroll and benefits	8
Other non-current assets	1
Other long-term liabilities	0
Accounts payable and other accrued liabilities	13
Accrued payroll and benefits	8
Other long-term liabilities	0
Net cash used in by operating activities	-117
Proceeds from sales of marketable securities	175
Purchases of marketable securities	29
Purchases of property and equipment	2
Intangible asset additions	4
Net cash provided by (used in) investing activities	141
Purchases of property and equipment	2
Net cash provided by (used in) investing activities	141
Follow-On Public Offering	99
2023 ATM Prospectus	19
Proceeds from term loan	10
Proceeds from sale of common stock under employee stock purchase plan	1
Proceeds from Stock Options Exercised	1
Net cash provided by financing activities	130
Net increase (decrease) in cash and cash equivalents	153
Interest expense paid in cash	3
Right-of-Use Asset Obtained in Exchange for Operating Lease Liability	2
Capital Expenditures Incurred but Not yet Paid	0
Interest expense paid in cash	3
Capital Expenditures Incurred but Not yet Paid	0
Right-of-Use Asset Obtained in Exchange for Operating Lease Liability	2
Proceeds from sales of marketable securities	175
Purchases of marketable securities	29
Purchases of property and equipment	2
Intangible asset additions	4
Net cash provided by (used in) investing activities	141
Purchases of property and equipment	2
Net cash provided by (used in) investing activities	141
Follow-On Public Offering	99
2023 ATM Prospectus	19
Proceeds from term loan	10
Proceeds from sale of common stock under employee stock purchase plan	1
Proceeds from Stock Options Exercised	1
Net cash provided by financing activities	130
Net increase (decrease) in cash and cash equivalents	153
Interest expense paid in cash	3
Right-of-Use Asset Obtained in Exchange for Operating Lease Liability	2
Capital Expenditures Incurred but Not yet Paid	0
Interest expense paid in cash	3
Capital Expenditures Incurred but Not yet Paid	0
Right-of-Use Asset Obtained in Exchange for Operating Lease Liability	2